SIGA’s CEO, Dr. Phillip Gomez, and Garrett Ingram, President, CEO of Cipla Therapeutics, discuss the companies’ recently announced collaboration to provide the U.S. government with solutions for its biothreat and public health needs, with a focus on tackl
SIGA is proud to share that Chief Scientific Officer Dr. Dennis Hruby will be recognized at the upcoming World Microbe Forum taking place online June 20th-24th for receiving the ASM Award for Applied and Biotechnological Research
SIGA Technologies to Host Business Update Call on May 6th, 2021 Following Release of First Quarter 2021 Financial Results
Cipla Therapeutics and SIGA Technologies Announce Strategic Partnership to support innovation and provide access to novel antibacterial drugs against biothreats
SIGA Technologies to Host Business Update Call on March 4, 2021 Following Release of Year End 2020 Financial Results
SIGA Announces Public Health Agency of Canada Contract Award to Purchase Up To Approximately $33 Million of Oral TPOXX®
Julian Nemirovsky has served as a director of SIGA since December of 2020. He currently serves as Senior Vice President, Capital Markets at MacAndrews & Forbes, where he is responsible for managing all capital-structure matters relating to the firm’s portfolio companies and new investments. Prior to joining MacAndrews in 2020, he spent 9 years at MidOcean Credit Partners, where he held the title of Principal and Portfolio Manager. In that role, he was responsible for management of over $1 billion of assets across several opportunistic credit strategies including long/short hedge funds and illiquid credit drawdown funds. Prior to joining MidOcean in 2011, he was an Associate at Union Capital, a lower-middle market private equity firm. He began his career in 2006 as an Analyst in Goldman Sachs’ Leveraged Finance group within the Investment Banking division. Julian holds a BBA from Baruch College and an MBA from the Tuck School of Business (Dartmouth).